MedCity News November 19, 2024
Marissa Plescia

The DEA recently announced the third extension of Covid-19 flexibilities for the virtual prescribing of controlled substances. Telehealth advocates applaud this move but remain hopeful for a more permanent solution in the future.

Several telehealth advocates are coming out in support of the Drug Enforcement Administration’s (DEA) third extension of Covid-19 telehealth flexibilities for the prescribing of controlled substances. However, they argue that more work needs to be done to make these flexibilities permanent.

The flexibilities, introduced in 2020, permit providers to prescribe some controlled substances virtually without first requiring an in-person visit. These flexibilities were set to expire at the end of the year, but will now expire at the end of 2025 with the third extension announced last...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Govt Agencies, Patient / Consumer, Provider, Technology, Telehealth
Telehealth groups call for urgent action as Medicare flexibility deadline looms
Health care package winners and losers
Wisp Teams Up with Nourish to Combine GLP-1s with Nutrition Counseling
Temporary Federal Funding Bill Addresses SUPPORT Act Reauthorization, Ghost Networks and Telehealth Flexibilities
Stopgap funding bill includes sweeping PBM reform, preserves telehealth flexibilities

Share This Article